Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$131.18 ▲ +1.15
(+0.88%)
MKT CAP: $14.89B • VOL: 1.88M
52W L $61 52W H $134
HALO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.40B | $1.02B | $829.3M |
| YoY Revenue Growth % | +37.6% | +22.4% | — |
| Gross Profit | $1.17B | $855.9M | $364.9M |
| Gross Margin % | 83.6% | 84.3% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $469.0M | $551.5M | $337.6M |
| Operating Margin % | 33.6% | 54.3% | 40.7% |
| Net Income (GAAP) | $316.9M | $444.1M | $281.6M |
| EBITDA (Normalized) | $474.6M | $560.0M | $367.4M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $651.6M | $479.1M | $388.6M |
| Capital Expenditures (CapEx) | $7.0M | $10.7M | $37.3M |
| Free Cash Flow (FCF) | $644.6M | $468.4M | $351.3M |
| FCF Margin % | 46.2% | 46.1% | 42.4% |
| Return on Invested Capital (ROIC %) | 18.0% | 24.8% | 5.4% |
| Cash & Short-Term Equivalents | $133.8M | $115.8M | $900.8M |
| Total Debt (Short + Long Term) | $2.14B | $1.51B | $1.92B |
| Total Stockholders' Equity | $48.8M | $363.8M | $3.93B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HALO.